Calyxo Secures $40M Series F Funding Round

Why It Matters

The infusion of $40 million accelerates Calyxo’s path to market, potentially reshaping kidney‑stone care and delivering strong returns for a sector that’s seeing heightened VC interest.

Key Takeaways

• Calyxo raised $40M in a Series F round
• Lead investors: Ally Bridge Group and Janus Henderson
• Existing backers Questa, Avidity Partners, CRG reinvested
• Funding targets RISC‑V‑enabled kidney‑stone devices
• Series F highlights rising medtech VC activity

Pulse Analysis

The medtech landscape is experiencing a surge of late‑stage capital as investors chase technologies that can both improve outcomes and lower procedural costs. Calyxo’s $40 million Series F, led by Ally Bridge Group and Janus Henderson, reflects this trend, positioning the company among a select group of startups that have secured multi‑digit funding beyond the growth stage. Such rounds are typically reserved for firms with proven product pipelines and clear regulatory pathways, indicating that Calyxo has demonstrated sufficient traction to merit substantial investor confidence.

Kidney stones affect roughly 1 in 10 Americans annually, creating a $5 billion market for treatment devices and procedures. Calyxo’s approach leverages RISC‑V processor IP to deliver real‑time imaging and precision control within a compact, disposable catheter system. By integrating open‑source hardware, the company can iterate faster and reduce manufacturing costs, offering urologists a tool that promises higher stone‑free rates with fewer complications. This technological edge differentiates Calyxo from legacy lithotripsy and laser platforms that dominate current practice.

For the venture community, the round signals that capital is flowing toward medtech innovators that combine clinical need with cutting‑edge electronics. The participation of both new and existing investors suggests a consensus that Calyxo’s roadmap—spanning FDA clearance, commercial rollout, and potential international expansion—is both realistic and lucrative. As the company moves toward market entry, its success could set a benchmark for future RISC‑V‑based medical devices, encouraging further investment in open‑hardware solutions across the broader healthcare ecosystem.

Deal Summary

Medical device company Calyxo announced the closing of a $40 million Series F financing round on April 15, 2026. The round was led by Ally Bridge Group and Janus Henderson Investors, with participation from Questa Capital, Avidity Partners, and CRG. The capital will support Calyxo's development of innovative kidney stone treatment solutions.